US Patent Issued to MINDSET PHARMA on March 31 for "Scalable synthetic route for psilocin and psilocybin" (Canadian Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,060, issued on March 31, was assigned to MINDSET PHARMA INC. (St. Laurent, Canada).

"Scalable synthetic route for psilocin and psilocybin" was invented by Abdelmalik Slassi (Mississauga, Canada) and Joseph Araujo (Grimsby, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disor...